Lifestyle Intervention for Prevention of Type 2 Diabetes in Primary Health Care
暂无分享,去创建一个
Sirkka Keinänen-Kiukaanniemi | Jaakko Tuomilehto | Leena Moilanen | L. Niskanen | J. Tuomilehto | S. Keinänen-Kiukaanniemi | M. Uusitupa | T. Saaristo | E. Korpi-hyövälti | J. Saltevo | L. Moilanen | Markku Peltonen | H. Oksa | M. Vanhala | J. Jokelainen | Jari Jokelainen | Matti Uusitupa | Mauno Vanhala | Markku Peltonen | Heikki Oksa | Leo Niskanen | Eeva Korpi-Hyövälti | Juha Saltevo | Timo Saaristo | E. Korpi-Hyövälti
[1] J. G. Ryan,et al. Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus. , 2009, Gender medicine.
[2] G. Nichols,et al. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. , 2008, The American journal of medicine.
[3] E. Vartiainen,et al. Do changes in cardiovascular risk factors explain changes in mortality from stroke in Finland? , 1995, BMJ.
[4] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[5] J M Dekker,et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. , 2001, JAMA.
[6] E. Barrett-Connor,et al. Sex Differences in Diabetes Risk and the Effect of Intensive Lifestyle Modification in the Diabetes Prevention Program , 2008, Diabetes Care.
[7] Jaakko Tuomilehto,et al. The diabetes risk score: a practical tool to predict type 2 diabetes risk. , 2003, Diabetes care.
[8] Jaakko Tuomilehto,et al. A practical tool to predict type 2 diabetes risk , 2003 .
[9] E. Vartiainen,et al. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland , 1994, BMJ.
[10] K. Kosaka,et al. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. , 2005, Diabetes research and clinical practice.
[11] P. Zimmet,et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[12] Jaakko Tuomilehto,et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. , 2003, Diabetes care.
[13] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[14] O. Pedersen,et al. Progression to Impaired Glucose Regulation and Diabetes in the Population-Based Inter99 Study , 2008, Diabetes Care.
[15] G. Egger. Health, "illth," and economic growth: medicine, environment, and economics at the crossroads. , 2009, American journal of preventive medicine.
[16] K. Borch-Johnsen,et al. Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study, Denmark , 2008, Diabetologia.
[17] M. Molitch. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. , 2003, Diabetes care.
[18] J. Lindström,et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study , 2006, The Lancet.
[19] C. Snehalatha,et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) , 2006, Diabetologia.
[20] Richard Barnett,et al. Diabetes mellitus. , 1993, The Medical journal of Australia.
[21] Sirkka Keinänen-Kiukaanniemi,et al. National type 2 diabetes prevention programme in Finland: FIN-D2D , 2007, International journal of circumpolar health.
[22] M. Laakso,et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.
[23] Alain Golay,et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.
[24] A. Rissanen,et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.
[25] Bo Zhang,et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study , 2008, The Lancet.